A very recent clinical trial (DAPA-HF Trial) demonstrated that in patients with heart failure and reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower in those who received SGLT2 inhibitor dapagliflozin than in those who received placebo, regardless of the presence or absence of diabetes (McMurray et al., 2019; Nassif et al., 2019). The gene discussed is SLC5A2; the disease is diabetes mellitus.